

# Correction

## Correction: El-Shiekh et al. Luteolin 4'-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo. *Molecules* 2023, 28, 2609

Riham A. El-Shiekh <sup>1,\*</sup> , Mai A. Elhemely <sup>2,3,\*</sup>, Ibrahim A. Naguib <sup>4</sup> , Sarah I. Bukhari <sup>5</sup>  and Rana Elshimy <sup>6,7</sup> 

- <sup>1</sup> Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr el Aini St., Cairo 11562, Egypt
  - <sup>2</sup> School of Medical Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M20 4GJ, UK
  - <sup>3</sup> Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt
  - <sup>4</sup> Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; i.abdelal@tu.edu.sa
  - <sup>5</sup> Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; sbukhari@ksu.edu.sa
  - <sup>6</sup> Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Giza 12451, Egypt; rana.elshimy@acu.edu.eg
  - <sup>7</sup> Department of Microbiology and Immunology, Egyptian Drug Authority, Giza 12511, Egypt
- \* Correspondence: riham.adel@pharma.cu.edu.eg (R.A.E.-S.); mai.ali@manchester.ac.uk (M.A.E.)

### Missing Citation

In the original publication [1], “Eloutify, Y.T.; El-Shiekh, R.A.; Ibrahim, K.M.; Elshimy, R.; Avula, B.; Katragunta, K.; Khan, I.; Meselhy, M.R. Bioassay-guided isolation of Antimicrobial Components and LC/QToF Profile of *Plumeria obtusa*: Potential for the treatment of Antimicrobial Resistance. *ACS Omega* 2023, 8, 6476–6491” was not cited. The citation has now been inserted in the legend of Figure 5 and the last paragraph of Section 4.6.2 and should read:

**Figure 5.** Histological sections of lungs stained with H&E and scoring of pulmonary lesions in a model of mice infected with MDR *K. pneumoniae*. (a) Mice infected with *K. pneumoniae* (X = 400), (b) mice infected with *K. pneumoniae* and then treated with gentamycin (GEN) (X = 200) [21], and (c) mice infected with *K. pneumoniae* and then treated with luteolin 4'-neohesperidoside (L4N) (X = 200).

### The Last Paragraph of Section 4.6.2

Four mice from each group were dissected, and kidneys and large intestines were isolated from cages 1, 3, 6, and 7, while lungs were isolated from cages 1, 2, 4, and 5. All organs were subjected to further histopathological examination [21,37]. The organs were examined and compared to the control group. They were scored according to the extent of different pathological features.

### References

With this correction, the order of some references has been adjusted accordingly.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



Received: 17 February 2025  
Accepted: 4 March 2025  
Published: 13 March 2025

**Citation:** El-Shiekh, R.A.; Elhemely, M.A.; Naguib, I.A.; Bukhari, S.I.; Elshimy, R. Correction: El-Shiekh et al. Luteolin 4'-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo. *Molecules* 2023, 28, 2609. *Molecules* 2025, 30, 1283. <https://doi.org/10.3390/molecules30061283>

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## Reference

1. El-Shiekh, R.A.; Elhemely, M.A.; Naguib, I.A.; Bukhari, S.I.; Elshimy, R. Luteolin 4'-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo. *Molecules* **2023**, *28*, 2609. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.